secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001599298-25-000088
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics Q1 net loss widens to $62.9M; ivonescimab gets second China approval
--------------------------------------------------------------------------------

- GAAP net loss $62.9M ($0.09/share) vs $43.5M ($0.06) in Q1 2024; R&D expenses rose to $51.2M.
- Cash and investments $361.3M at Mar 31, 2025 vs $412.3M at Dec 31, 2024; non-GAAP op expenses $55.7M.
- Ivonescimab showed statistically significant PFS superiority vs tislelizumab in HARMONi-6 trial (squamous NSCLC).
- China NMPA approved ivonescimab for second indication (1L NSCLC with PD-L1+); interim OS HR=0.777.
- Appointed Robert LaCaze as CCO; enrollment ongoing in HARMONi-3 and HARMONi-7; HARMONi topline expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/0001599298-25-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000088/smmt-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer